EUCTR2019-004812-73-NL招募中1 期
The influence of pharmacological conditioning with S-ketamine on pain sensitivity in patients with Fibromyalgia Syndrome
eiden University0 个研究点目标入组 36 人开始时间: 2022年5月27日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
入选标准
- •-Diagnosed with FMS by a rheumatologist
- •-Age between 18 and 75 years old
- •-Dutch speaking participants
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •-A medical diagnosis other than fibromyalgia explaining the chronic pain symptoms.
- •-Presence of hypertension or any other severe cardiovascular co-morbidity (e.g., heart failure (NYHA III or IV), neuromuscular diseases, pulmonary obstructive & restrictive diseases, kidney failure (eGFR = 60), liver diseases or epilepsy)
- •-Presence of any severe psychiatric disease not related to symptoms of FMS (e.g., schizophrenia, schizoaffective disorders, severe anxiety or depression (HADS > 15), bipolar disorder, dissociative personality disorder, or (previous) addiction to strong analgesics.
- •-Presence of any allergy for S(+)-ketamine, midazolam, ondansetron or flumazenil
- •-Long term use of medicine that is contra-indicated when administering S(+)-ketamine or midazolam: NMDA-receptor antagonists, parasympathomimetics (e.g., bronchodilators), thyroid hormones, vasopressin, CYP3A4 liver enzyme inhibitors (e.g., verapamil, diltiazem, or certain antibiotics), CYP3A4 liver enzyme inductors (e.g., rifampicin, carbamazepine, fenytoin), and strong opioids (e.g., morphine, fentanyl, heroin)
- •-Previous experience(s) with S(+)-ketamine in a medical setting or previous experience with recreational racemic Ketamine use.
- •-Use of painkillers different than usual dose of treatment on the day of experimentation.
- •-Use of alcohol or drugs 24 hours prior to the hospital visits
- •-Use of caffeine 12 hours prior to the hospital visits
- •-Body weight > 100kg or BMI >35
- •-Presence of pregnancy or lactation
- •-Presence of an ICD, pacemaker or implanted medication pump
- •-Presence of chronic pain at the local site of experimental pain stimuli or monitoring devices.
- •-Implanted materials in either arm (e.g., non-removable piercings)
研究者
相似试验
招募中
不适用
The influence of pharmacological conditioning with S-ketamine on pain sensitivity in patients with Fibromyalgia SyndromeChronische pijnstoornisDiffuse myofascial pain syndromeMuscular RheumatismNL-OMON54449niversiteit Leiden36
招募中
不适用
Safety and efficacy of conditioning regimen with once-daily intravenous busulfan and fludarabine or cyclophosphamide for allogeneic hematopoietic stem cell transplantation in acute myelogenous leukemia or myelodysplastic syndromeacute myelogenous leukemia, myelodysplastic syndromeJPRN-UMIN000015647Second Department of Internal Medicine, Shinshu University of School of Medicine30
已完成
2 期
Safety and efficacy of conditioning regimen with fludarabine and targeted dose intravenous busulfan for elderly patinetsAcute myeloid leukemia, Myelodysplastic syndromeJPRN-UMIN000010546Chiba University Hospital, Department of Hematology25
进行中（未招募）
1 期
Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study (RICMAC) - RICMAC MDS/sAMde novo-MDS, treatment-induced MDS (T MDS), AML arising from MDS, treatment-induced AMLMedDRA version: 9.1 Level: PT Classification code 10000880 Term: Acute myeloid leukaemiaMedDRA version: 9.1 Level: LLT Classification code 10028533 Term: Myelodysplastic syndromeEUCTR2005-002011-24-GBEuropean Group for Blood and Marrow Transplantation160
进行中（未招募）
不适用
Dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation in patients with MDS or sAML: A randomised phase III study (RICMAC) - RICMAC MDS/sAMde novo-MDS, treatment-induced MDS (T MDS), AML arising from MDS, treatment-induced AMLMedDRA version: 9.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaMedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeEUCTR2005-002011-24-BEEuropean Group for Blood and Marrow Transplantation160